Recombinant activated factor seven in pediatric cardiac surgery-does thrombotic risk outweigh hemostatic benefit?
Sign Up to like & getrecommendations! Published in 2019 at "Translational pediatrics"
DOI: 10.21037/tp.2019.10.04
Abstract: Therapies employed to attenuate perioperative bleeding following cardiopulmonary bypass (CPB) in children include antifibrinolytic therapy, allogenic blood product transfusion, and recombinant factor concentrates. Recombinant activated factor seven (rFVIIa) (Novoseven RT, Novo Nordisk A/S, Denmark) is… read more here.
Keywords: factor seven; activated factor; seven pediatric; pediatric cardiac ... See more keywords